Pfizer Obtains Amplyx to Broaden its Contagious Disease Portfolio
Click on this link to read complete press release/ article|Ref: Pfizer|Image: PRNewswire.
The acquisition expands the anti-infectives pipeline with the addition of Amplyxs P-II prospect, Fosmanogepix (APX001) which is being assessed in both IV and oral formulas for the treatment of clients with invasive fungal infections
Pfizer likewise retains ownership of the Amplyx early-stage pipeline, consisting of antiviral (MAU868) and antifungal (APX2039) therapies. The acquisition follows an initial equity investment by Pfizer in December 2019 as part of Amplyxs Series C funding
Fosmanogepix has shown broad-spectrum activity in-vitro and showed broad distribution to various tissues, including brain, kidney, lung, and eye